Real-world corticosteroid utilization patterns in patients with metastatic castration-resistant prostate cancer in 2 large US administrative claims databases

American Health and Drug Benefits

Volumn 6, Issue 6, 2013, Pages

  Lafeuille, Marie Hélène ^a   Gravel, Jonathan ^a   Grittner, Amanda ^a   Lefebvre, Patrick ^a   Ellis, Lorie ^b   Scott McKenzie, R ^b  

^a GROUPE D ANALYSE   (Canada)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; BICALUTAMIDE; CARBOPLATIN; CONJUGATED ESTROGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; ESTROGEN; FLUTAMIDE; KETOCONAZOLE; MITOXANTRONE; NILUTAMIDE; PREDNISONE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EVALUATION; COMORBIDITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG USE; DRUG UTILIZATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES;

EID: 84882616849     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kohli M, Tindall DJ. New developments in the medical management of prostate cancer. Mayo Clin Proc. 2010;85:77-86.
2. Sartor O, Michels RM, Massard C, de Bono JS. Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist. 2011;16:1487-1497.
3. American Cancer Society. What are the key statistics about prostate cancer? Revised May 15, 2013. www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Accessed March 3, 2013.
4. Scher HI, Halabi S, Tannock I, et al; for the Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148-1159.
5. Saad F, Hotte SJ; for the Canadian Urologic Oncology Group, and the Canadian Urological Association. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J. 2010;4:380-384.
6. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180-1192.
7. Toren PJ, Gleave ME. Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl. 2013;15:342-349.
8. Seruga B, Tannock IF. Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol. 2011;29:3686-3694.
9. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989;7:590-597.
10. Tannock IF, de Wit R, Berry WR, et al; for the TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
11. Zytiga (abiraterone acetate) tablets [prescribing information]. Horsham, PA: Janssen Biotech, Inc; December 2012.
12. Jevtana (cabazitaxel) injection [prescribing information]. Bridgewater, NJ: sanofi-aventis US LLC; 2013.
13. Provenge (sipuleucel-T) suspension [prescribing information]. Seattle, WA: Dendreon Corporation; June 2011.
14. Xtandi (enzalutamide) capsules [prescribing information]. Northbrook, IL: Astellas Pharma US, Inc; August 2012.
15. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®): prostate cancer. Version 2.2013. March 11, 2013. www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed May 21, 2013.
16. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
18. Scher HI, Fizazi K, Saad F, et al. Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. J Clin Oncol. 2013;31(6 suppl 6):Abstract 6.
19. MacVicar GR, Hussain MH. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. Curr Opin Oncol. 2013;25:252-260.
20. Heidenreich A, Rawal SK, Szkarlat K, et al. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2013;24: 329-336.
21. Higano CS, Crawford ED. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol. 2011;29(6 suppl):S1-S8.